| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Head and Neck Cancer Research Division, Department of OtolaryngologyHead and Neck Surgery, 2 Department of Oncology Biostatistics, and 3 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
| ABSTRACT |
|---|
|
|
|---|
Experimental Design: DNA from mild, moderate, and severe dysplasias, as well as invasive tumors and normal mucosal cells, was extracted. Using quantitative polymerase chain reaction, mitochondrial to nuclear DNA ratios were determined by quantification of cytochrome c oxidase subunit 1 (CoxI) and ß-actin genes.
Results: Mean CoxI/ß-actin DNA ratios for mild, moderate, and severe premalignant lesions were 0.0529, 0.0607, and 0.1021, respectively. The mean ratio for the normal mucosal cells contained in saliva was 0.0537, whereas the mean ratio for tumors was 0.1667. As a whole, our experimental model demonstrated significance (P = 0.0358). Comparisons between individual categories showed borderline significance when compared with the normal group, with P values of 0.0673, 0.0747, and 0.0824 for moderate and severe dysplasia and invasive tumor, respectively.
Conclusions: Head and neck squamous cell carcinomas arise through premalignant intermediates and may be merely morphologic manifestations of accumulated genetic alterations. In keeping with this molecular tumor progression model, our study shows that mtDNA increases according to histopathologic grade, a phenomenon that may be a feedback mechanism that compensates for a generalized decline in respiratory chain function. Therefore, high mtDNA content may be another marker of genetic alteration, a measure of relative DNA injury, and a surrogate measure of histopathologic grade.
| INTRODUCTION |
|---|
|
|
|---|
Interestingly, mtDNA copy number appears to increase with age in various human tissues (10) as well as in cells affected by the exogenous application of an oxidative agent such as hydrogen peroxide (11) . This increase in mitochondrial copy number has been viewed as a potential compensatory effect for the generalized decline in mitochondrial respiratory function (12) . Thus, mtDNA content is directly proportional to oxidative DNA damage yet inversely proportional to function.
Oxidative DNA damage has been implicated in the development of many human cancers through the mutation and dysregulation of critical genes. Molecular damage created in part by oxidative insults can drive the progression of normal tissues to cancer. First proposed in colorectal cancer, the tumor progression model states that normal tissues progress to cancer through a series of premalignant intermediates (13) . The histopathological appearance of these stages of tumorigenicity is caused by a stepwise accumulation of critical genetic alterations. Specifically, alterations of mitochondria have also been discovered in a variety of primary human cancers including gastric (14) , esophageal (15) , thyroid (16) , breast (17) , and nonsmall-cell lung cancer (18) . In head and neck premalignant lesions, alterations in the mtDNA poly C-tract, an important area located in the mitochondrial D-loop, are proportional to degrees of premalignancy (19) .
It is established that reactive oxygen species damage DNA, increase mitochondrial content, and increase the potential for cancer development. In addition, it has been demonstrated that cancer develops through a series of premalignant intermediates in keeping with a tumor progression model. Therefore, our goal was to establish a link between a spectrum of head and neck premalignant lesions and mitochondrial content in the context of normal mucosal cells and tumors. If such a link can be established, quantification of mtDNA content may serve as a molecular marker that may have use in evaluating the tumorigenic potential of head and neck lesions. Our study explored the relationship between mtDNA content and a spectrum of head and neck tissues of differing histopathological grades.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Ten-micron sections were cut from paraffin blocks and microdissected using hematoxylin and eosin-stained slides as a guide. The samples were placed in xylene for 12 hours with subsequent centrifugation at 13,500 rpm. The tissue pellets were then digested in 1% SDS/proteinase K over 48 hours at 48°C. Subsequent phenol-chloroform extraction and EtOH precipitation were performed, and samples were stored at 20°C. Sixteen paraffin-embedded head and neck squamous cell carcinoma (HNSCC) tumors were processed in the same manner.
Local community organizations with a significant proportion of members with tobacco exposure were contacted for participation in a screening study for upper aerodigestive tract malignancy. Informed consent was obtained by an institutional review board-approved protocol, and 655 participants with a variety of ages and risk factors were recruited. At the screenings, subjects filled out a detailed health/demographic questionnaire, provided blood and saliva samples, and received a physical examination by a head and neck surgeon. To procure mucosal cells from the upper aerodigestive tract, subjects were given 25 mL of saline to swish, gargle, and brush. The patients were instructed to brush their buccal mucosa. The resultant wash was then consolidated.
Although these saliva samples were from a mixed population with and without smoking histories, their oral mucosal cells were considered normal because their physical exams were devoid of suspicious lesions. Each wash sample underwent centrifugation at 2,500 rpm for 15 minutes. The supernatant was discarded, and the cell pellet was retained. One percent SDS/proteinase K (0.5 mg/mL) was added, and the resultant mixture was placed at 48°C for 72 hours. Subsequent DNA extraction was performed through phenol-chloroform and EtOH precipitation.
Quantitative Polymerase Chain Reaction.
A Perkin-Elmer/ABI 7900 thermocycler was used to perform real-time polymerase chain reaction (PCR) amplification for ß-actin and mtDNA regions for cytochrome c oxidase I (CoxI). CoxI primer sequences used previously were used in this study (21)
. Primers were custom made and obtained from Invitrogen (Carlsbad, CA). The CoxI region was amplified using forward primer 5'-TTCGCCGACCGTTGACTATTCTCT-3' and reverse primer 5'-AAGATTATTACAAATGCATGGGC. ß-Actin amplification was done using forward primer 5'-ACCCACACTGTGCCCATCTAC-3' and reverse primer 5'-TCGGTGAGGATCTTCATGAGGTA-3'. All TaqMan probes (Applied Biosystems, Foster City, CA) were 5'-FAM and 3'-TAMRA labeled. CoxI probe 6-FAM-AACGACCACATCTACAACGTTATCGTCAC-TAMRA and ß-actin probe 6-FAM-ATGCCCTCCCCCATGCCATCC-TAMRA were used. Probe and primer combinations were designed to avoid amplification of pseudogenes, by performing BLAST analysis of a primers and probes. PCR amplifications were carried out in buffer containing 16.6 mmol/L ammonium sulfate, 67 mmol/L Trizma, 2.5 mmol/L MgCl2, 10 mmol/L ß-mercaptoethanol, 0.1% dimethyl sulfoxide, 600 nmol/L each of forward and reverse primers, 200 nmol/L TaqMan probe, 0.6 unit of platinum Taq polymerase, and 2% Rox reference dye. Five hundred picograms of DNA were used to amplify mitochondrial regions, whereas 10 ng were used to amplify ß-actin, a single copy gene. The real-time PCR reactions were performed in triplicate for each gene. Standard amplification curves for CoxI and ß-actin genes were obtained using JHU-O11 cell line DNA.
Statistical Analysis.
The major statistical end point in this study was the comparison of the mean mtDNA content of specimens taken from five different types of head and neck lesions. A regression model was fit to test if the means from the mild, moderate, severe, and tumor groups were different from the normal group. Mitochondrial DNA values were transformed with the log transformation for this analysis. Means and SDs were determined on the natural scale. All statistical computations were performed using the SAS system (SAS Institute Inc., Cary, NC), and a two-sided P value is reported.
| RESULTS |
|---|
|
|
|---|
|
|
|
We performed an analysis of variance to examine the significance of our findings as described (see Materials and Methods). As a whole, our model demonstrated significance (P = 0.0358). Comparisons between individual categories showed borderline significance when compared with the normal (saliva) group, with P values of 0.0673, 0.0747, and 0.0824 for moderate dysplasia, severe dysplasia, and invasive tumor, respectively.
| DISCUSSION |
|---|
|
|
|---|
Our hypothesis is that in upper aerodigestive mucosal cells, mtDNA experiences alterations and resultant dysfunction as a reflection of progression to a malignant phenotype. In response to this dysfunction, mitochondrial content increases to compensate for its functional deficiencies. Our study supports this hypothesis by showing not only an increase in mtDNA/nDNA ratios but also a consistent and proportional relationship between mitochondrial content and different degrees of histopathologic grade. This implies that a progressive increase in mtDNA content is a hallmark of tumor progression in HNSCC and occurs in a manner similar to that found by oxidative injury.
One potential limitation is our relatively small numbers of premalignant head and neck lesions, tissues that are difficult to obtain in large numbers. Although the differences in values closely approach significance, the addition of greater sample numbers may be necessary to definitively demonstrate differences between each degree of dysplasia. Another limitation to our study was the relative dearth of information with respect to smoking that accompanied our archival premalignant tissues. If tobacco consumption information were readily available, then direct conclusions could be made regarding the relationship of smoking to both mtDNA/nDNA ratio and degrees of premalignancy. Instead, our data illustrate the relationship between mtDNA/nDNA ratios and histopathology only. However, because numerous previous studies have outlined a direct relationship between dysplastic tissues and smoking, we can safely assume that this relationship exists in our study as well.
The age disparity among the patients from whom the samples were collected was also an initial concern because of previously published associations between increased mitochondrial content and advanced age. Premalignant and saliva samples corresponded to patients in their early 60s, whereas tumor-bearing patients had a median age of 40 years. This disparity became less of a concern when we discovered relative increases in tumors despite these patients being 20 years younger. Therefore, we have likely underestimated the difference in mtDNA content between premalignant lesions.
Originally developed from colorectal cancer (13) , the tumor progression model, which relates cancer development to a stepwise accumulation of genetic alterations, has been extended to HNSCCs (25) . Our results support this model by revealing a progressive increase of mitochondrial content across a spectrum of benign, premalignant, and malignant lesions.
This study also complements previous research that explored the relationship between mitochondrial C-tract alterations and oral premalignancies of different histopathological grade (19) . The mitochondrial C-tract region, a mononucleotide repeat of cytosine residues located in the D-loop region of the mitochondrial genome, had previously been shown to be altered in HNSCCs (26) . Ha et al. (19) observed significant C-tract alteration rates of 22%, 37%, and 62% in benign hyperplastic, premalignant, and carcinoma in situ tissues, respectively. These observations and ours provide evidence that increases in both mutational alterations of mtDNA and mitochondrial content are directly proportional to histologic grade.
These dual phenomena may be explained by a positive feedback mechanism whereby the cell, to compensate for a generalized decline in respiratory chain function caused by mutagenic exposure, up-regulates the replication of mitochondria. As such, measurement of mtDNA content may reflect genetic alteration or DNA injury. However, impaired oxidative phosphorylation may also result in increased oxidative injury to both nuclear and mtDNA, resulting in additional mutagenic insult.
In summary, mtDNA alterations and content increases are common progression events in the development of HNSCC from benign lesion to premalignant intermediates and, ultimately, to tumors. Although this relationship may be simply associated with HNSCC carcinogenesis, mitochondrial derangements demonstrate characteristic behavior of progression events that are etiologic in tumor development. This gives support to investigation of the functional consequences of mitochondrial alteration in the development of HNSCC.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Joseph A. Califano, Department of Otolaryngology-Head and Neck Surgery, 601 North Caroline Street, 6th Floor, Baltimore, MD 21287-0910. E-mail: jcalifa{at}jhmi.edu
Received 4/16/04; revised 9/ 7/04; accepted 9/16/04.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. K. Mithani, I. M. Smith, S. Zhou, A. Gray, W. M. Koch, A. Maitra, and J. A. Califano Mitochondrial Resequencing Arrays Detect Tumor-Specific Mutations in Salivary Rinses of Patients with Head and Neck Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7335 - 7340. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E.W. Cohen A Disturbance in the Force Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., August 1, 2007; 13(15): 4317 - 4319. [Full Text] [PDF] |
||||
![]() |
W.-W. Jiang, E. Rosenbaum, E. Mambo, M. Zahurak, B. Masayesva, A. L. Carvalho, S. Zhou, W. H. Westra, A. J. Alberg, D. Sidransky, et al. Decreased Mitochondrial DNA Content in Posttreatment Salivary Rinses from Head and Neck Cancer Patients Clin. Cancer Res., March 1, 2006; 12(5): 1564 - 1569. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |